A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Subjects
Latest Information Update: 25 Jun 2020
At a glance
- Drugs TAK 994 (Primary)
- Indications Narcolepsy
- Focus Adverse reactions
- Sponsors Takeda
- 22 Jun 2020 Status changed from active, no longer recruiting to completed.
- 29 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2020 Planned number of patients changed from 152 to 160.